The JUPITER trial: results, controversies, and implications for prevention.

@article{Ridker2009TheJT,
  title={The JUPITER trial: results, controversies, and implications for prevention.},
  author={Paul M. Ridker},
  journal={Circulation. Cardiovascular quality and outcomes},
  year={2009},
  volume={2 3},
  pages={
          279-85
        }
}
Statin therapy is effective at reducing cardiovascular event rates among those with prior myocardial infraction, stroke, diabetes, or overt hyperlipidemia, and current guidelines strongly recommend lipid-lowering therapy among these patient groups as an adjunct to aggressive lifestyle interventions. However, of the nearly 1.7 million heart attacks and strokes that occur annually in the United States, more than half occur among apparently healthy men and women with average or low levels of… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 54 CITATIONS, ESTIMATED 55% COVERAGE

By Jove! What is a clinician to make of JUPITER?

  • Archives of internal medicine
  • 2010
VIEW 4 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2009
2019

CITATION STATISTICS

  • 3 Highly Influenced Citations

  • Averaged 6 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 23 REFERENCES

Fohnseca FAH. A randomized trial of rosuvastatin to prevent venous thromboembolism [published online ahead of print

RJ Glynn, E Danielson
  • March 29,
  • 2009

Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial

DA Morrow, JA de Lemos, +6 authors E. Braunwald
  • Circulation
  • 2006